Xyliette

Method of action: Contraceptive, Endocrine Therapy, Estrogen-Progestational, Sex Hormones And Modulators Of The Genital System

Treatment option: Hormonal Contraceptives, Venous Thromboembolism, Birth Control, Thromboembolism

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xyliette

Xyliette: Defining the Type and Class of Medicine

Property	Description
Active ingredients	Ethinyl Estradiol, Levonorgestrel
Form	Oral Contraceptive Tablets (Coated)
Pharmacological class	Combined Hormonal Contraceptive (CHC)
General use	Contraception (Pregnancy prevention)
Origin	Synthetic hormones

Xyliette is a prescription-only medication classified as a Combined Hormonal Contraceptive (CHC) and is used for the general therapeutic purpose of pregnancy prevention. This product is defined as a fixed-dose combination containing two essential steroid components, an estrogen and a progestin, designed for systemic action upon oral route of administration. The combination of these two pharmacological classes, Estrogen and Progestin, places it within the broader group of Sex Hormone Derivatives. Clinical research supports the use of this type of hormonal combination in establishing reproductive control. Combined oral contraceptives are utilized as a method for preventing pregnancy. As such, this medicine provides reproductive control for patients requiring ongoing contraception.

The foundational identity of Xyliette aligns with a monophasic regimen, meaning the concentration of both active components remains constant across all active tablets within the monthly cycle. The primary purpose of the combined formulation is achieved by the inhibition of ovulation, supported by secondary protective changes such as the cervical mucus thickening and endometrial alteration.

Composition: The Synthetic Hormone Combination

The active ingredients in Xyliette are the generic substances Ethinyl Estradiol and Levonorgestrel, which are formulated into Oral Contraceptive Tablets. Ethinyl Estradiol serves as the Synthetic Estrogen component, while Levonorgestrel functions as the Synthetic Progestin. The use of Levonorgestrel as the progestin distinguishes this specific formulation from other combined oral contraceptives that utilize alternative synthetic progestogens. Ethinyl Estradiol is designated as a synthetic estrogen component used in various contraceptive formulations.

As a product of synthetic origin, Xyliette does not rely on natural extracts; rather, it utilizes these specific chemical entities to ensure pharmaceutical-grade consistency. The active components are combined with standard pharmaceutical excipients and housed within Coated Tablets, a formulation that optimizes its stability and oral bioavailability. The integration of both an estrogen and a progestin in a fixed combination defines the drug's fundamental nature and its function in providing consistent hormonal management for pregnancy prevention.

Regulatory References

What side effects are possible with Xyliette?

Possible Side Effects and Safety Information for Xyliette

Regulatory agencies categorize the safety profile of any medication based on comprehensive data from clinical trials and post-marketing surveillance. This approach ensures that patients and healthcare providers have a clear understanding of the documented risks.

Documented Adverse Reactions

The most common adverse reactions are typically those reported by 1% or more of patients in clinical trials. These often involve general systemic categories such as Gastrointestinal Disorders (e.g., nausea, vomiting, diarrhea) and Nervous System Disorders (e.g., headache, dizziness, fatigue). The complete list of reactions is formally classified by frequency (e.g., Common, Uncommon, Rare) in the official prescribing information.

Serious and Clinically Significant Risks

Serious adverse reactions, which are often rare but potentially life-threatening, are highlighted in the drug's safety label. These reactions include events that may require hospitalization, result in significant disability, or be fatal. Officially documented serious concerns may cover severe Cardiovascular Events (such as stroke or myocardial infarction), Severe Hypersensitivity Reactions, and specific organ toxicity, such as severe Hepatotoxicity (liver damage).

Safety Restrictions and Monitoring

The official safety information outlines specific contraindications—situations where the drug must not be used—such as known hypersensitivity to the active ingredient. Additionally, the label details mandatory precautions and warnings, which may require routine patient monitoring, such as periodic laboratory testing (e.g., liver function tests, complete blood counts) to detect potential serious adverse effects early. These monitoring requirements are critical for the safe administration of the medication across all patient populations.

The safety profile is formally structured to govern the understanding of risks, detailing frequency, system-organ class involvement, and serious adverse events without providing clinical advice or treatment recommendations.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Manifestations and Severity

Overdose with Xyliette, a combined hormonal contraceptive, is officially documented in regulatory sources as having low acute toxicity and is not likely to be life-threatening. The recognized clinical signs are generally mild. Documented overdose presentations primarily involve the gastrointestinal system and hormone-mediated effects. Common manifestations listed in regulatory documents include nausea and vomiting. Additionally, withdrawal bleeding or vaginal bleeding is a known symptom following acute ingestion. Other documented signs may include drowsiness and breast tenderness. A specific population consideration is that vaginal bleeding as a symptom is relevant only in females who have achieved menarche (onset of menstruation).

Emergency Actions and Management

Despite the low acute toxicity classification, all cases of known or suspected overdose require immediate response. The official regulatory guidance mandates patients to seek immediate medical attention. The required emergency action is to contact a poison control center or emergency room at once for clinical assessment and monitoring. Since no specific antidote is known for this combination of hormones, the required hospital management is limited to providing symptomatic and supportive treatment. This includes monitoring vital signs and conducting necessary tests as part of the observation protocol.

Therapeutic Uses of Xyliette

What Xyliette Treats: Main Uses and Benefits

Xyliette, a combined hormonal contraceptive, is primarily used for reproductive control and is relevant for the symptomatic management of several hormone-sensitive conditions. Its core application is to prevent pregnancy, and it is also applied across therapeutic domains involving cyclical discomfort and instability.

Reproductive Control and Proactive Family Planning

This primary therapeutic domain is dedicated to pregnancy prevention for women of reproductive age. The core benefit provided is that it supports patients seeking consistent reproductive control, which assists with maintaining functional stability for family planning. This application is applied in scenarios where additional management of discomfort is required.

Symptomatic Management of Menstrual and Hormonal Distress

This application supports the management of symptoms clustered around the menstrual cycle. Xyliette is commonly used to help with heavy menstrual blood loss (menorrhagia) and severe, debilitating cramps (dysmenorrhea), which contributes to easing the overall symptom load. It is also applied in addressing cycle irregularity, easing hormone-driven manifestations including moderate acne, and the emotional and physical burden of Premenstrual Dysphoric Disorder (PMDD). This use provides supportive relief and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Cyclical Distress
Xyliette is commonly used to help with symptoms related to physical discomfort, such as menorrhagia and dysmenorrhea, and may assist with maintaining functional stability.

Regulatory References

NIH MedlinePlus overview of Ethinyl Estradiol and Levonorgestrel

Eligibility and Restrictions for Use

Xyliette (Ethinyl Estradiol and Levonorgestrel) is officially indicated for use only by females of reproductive potential. Regulatory documents establish strict population eligibility rules, primarily centered on mitigating the risk of thromboembolic events, which are categorized as absolute contraindications.

Use is strictly contraindicated in women over 35 years of age who smoke due to the significantly increased risk of cardiovascular events. Absolute non-eligibility rules also apply to individuals with a current or history of venous or arterial thrombotic diseases (e.g., DVT, stroke), known thrombophilias, or migraine headaches with aura.

The medicine is further contraindicated in the presence of liver tumors or severe active liver disease, known or suspected breast cancer, and undiagnosed abnormal uterine bleeding. It is also contraindicated during known or suspected pregnancy. Use is not recommended while breastfeeding and must be discontinued around periods of prolonged immobilization from major surgery. The medicine is not indicated for use before menarche.

What should I know about interactions with other medicines?

The interaction profile for Xyliette, containing Ethinyl Estradiol and Levonorgestrel, is defined by regulatory restrictions and pharmacokinetic changes to hormone exposure, as documented in official government sources.

Formal Contraindications & Major Restrictions

Combination	Regulatory Restriction
Hepatitis C Regimens	Co-administration with ombitasvir/paritaprevir/ritonavir pm dasabuvir is contraindicated due to the risk of significant liver enzyme elevations (ALT).
Smoking and Age	Contraindicated in women over 35 years of age who smoke due to a significantly increased risk of serious cardiovascular events.
Migraine with Aura	Contraindicated in females with a history of migraine with aura due to an increased stroke risk.

Exposure-Altering Interactions

Medicines that are strong CYP enzyme inducers (e.g., certain anticonvulsants) may decrease the plasma concentrations of Ethinyl Estradiol and Levonorgestrel, resulting in reduced contraceptive effectiveness. Conversely, Xyliette may decrease the clearance of co-administered drugs like Caffeine and Tizanidine, thereby increasing their systemic exposure.

Specific Constraints

The bile acid sequestrant Colesevelam decreases the absorption of the Ethinyl Estradiol component and requires Xyliette to be administered at least 4 hours before Colesevelam. Furthermore, Xyliette may decrease glucose tolerance, affecting the efficacy of Antidiabetic Agents, a documented pharmacodynamic interaction. The use of the herbal product St. John's wort is restricted due to its enzyme-inducing properties.

Mechanism of Action

Central Suppression of the HPO Axis

The primary mechanism involves the Ethinyl Estradiol and Levonorgestrel components acting as agonists at their respective Estrogen (ER) and Progesterone (PR) receptors in the brain's regulatory centers. This continuous action creates a sustained negative feedback signal, which prevents the pituitary gland from releasing the necessary surge of Luteinizing Hormone (LH). This cascade results in anovulation—the complete biological suppression of egg release from the ovary—which is central to the drug's mechanism of action.

️ Peripheral Multi-Barrier Mechanisms

In addition to the central effect, the mechanism establishes two complementary peripheral barriers. Driven primarily by Levonorgestrel, the drug alters the tissue of the cervix and the uterus. The cervical glands produce thick, tenacious mucus that physically impedes sperm movement, while the uterine lining (endometrium) becomes thin and unreceptive. This layered action—sperm barrier and endometrial unreceptivity—provides a secondary and tertiary mechanism should the primary anovulatory mechanism be transiently lowered or overcome.

Dosage and Administration Information

How Xyliette is Used: Official Administration Guidelines

Xyliette is indicated for oral administration as a combined hormonal contraceptive tablet. The core principle of its use is a daily regimen where one tablet must be taken at the same time each day to maintain a consistent hormonal profile. The standard active dose typically contains 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol.

The drug follows a set cyclic regimen, commonly structured as 21 active tablets followed by 7 inactive tablets in a 28-day cycle, though extended cycles are also defined. Tablets must be swallowed whole and taken in the exact order directed on the pack to ensure correct sequence progression. Intake is standardized as without regard to meals and is intended for long-term, continuous use for the duration contraception is required.

Procedural rules govern the initiation and maintenance of the regimen. These include protocols for starting the first pack and detailed instructions for handling a missed active tablet to prevent cycle interruption. The product is not intended for use in postmenopausal women, and guidance is provided on the delay of initiation until four weeks postpartum in non-lactating individuals.

Recent Clinical Evidence

Xyliette: Recent Clinical Evidence

Evidence for Use in Pregnancy Prevention (Contraception)

Research examined this combined hormonal formulation primarily through large Phase 3 Randomized Controlled Trials (RCTs) and extensive Observational Cohort Studies. These studies were evaluated in healthy, sexually active women of reproductive age and monitored outcomes related to the suppression of the natural cycle. The core objective was to measure the occurrence of unintended pregnancies over a defined time interval.

Studies reported measurements of the number of unintended pregnancies observed over one year (13 cycles). Research describes that findings show patterns related to measurements gathered under conditions of perfect use in trials. Research indicates that there is a distinction between perfect-use rates observed in trials and typical-use rates experienced in daily life. Furthermore, data for certain groups remain insufficient, and some findings were derived from studies involving older contraceptives with similar but higher hormone doses.

Evidence for Symptom Management of Menstrual and Hormonal Distress

Research on Menstrual Blood Loss and Cramping

The research examined populations with heavy menstrual blood loss (menorrhagia) and debilitating cramps (dysmenorrhea). Studies explored outcomes related to physical discomfort using RCTs that compared the formulation against placebo or non-hormonal treatments. Outcomes monitored included physical discomfort and the frequency of analgesic use.

Studies reported measurements related to changes in menstrual blood loss volume and findings related to patient-reported pain severity scores. Findings describe patterns observed in the studies related to the reporting of pain medication use. Regarding limitations, follow-up durations were limited in many of these trials. This means there is limited information for long-term outcomes concerning the sustained maintenance of pain relief.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Xyliette (FAQ)

Q: How does the time of day I use Xyliette affect its effectiveness?

Regulatory information specifies that Xyliette must be taken at the same time each day. This consistent timing is described as necessary to maintain steady hormone levels that support the drug's contraceptive mechanism. Official product information contains established protocols regarding handling a missed active tablet.

Q: Does Xyliette cause drowsiness, making it difficult to drive?

The official product label lists dizziness and fatigue as possible side effects reported by users. Official information suggests patients assess their personal response to the medication before driving or operating complex machinery.

Q: Can Xyliette affect my ability to become pregnant (fertility)?

While in use, Xyliette works by biologically suppressing ovulation to prevent pregnancy. Official documents note that the risk of thromboembolic disease associated with combined oral contraceptives (COCs) gradually disappears after use is discontinued.

Q: Is Xyliette considered a maintenance treatment?

The regimen is described in regulatory documents as intended for long-term, continuous use while contraception is needed. This aligns with the understanding of it being an ongoing therapy.

Q: Can Xyliette cause changes in mood or anxiety?

Changes in mood, including depression or affect lability (rapid shifts in mood), are reported effects observed with combination oral contraceptives, according to official information.

Q: How quickly should I expect to see an effect from Xyliette?

The contraceptive mechanism of Xyliette is designed to begin working immediately if initiated as directed. However, official information describes that additional (non-hormonal) contraceptive methods may be warranted for the first seven to nine days of the first cycle, depending on the day the first pill is started.

Q: Are there any specific foods or drinks to avoid while using Xyliette?

Regulatory documents indicate that consumption of grapefruit or grapefruit juice may potentially increase the exposure of the active ingredients in the body. Alcohol is also listed in regulatory sources as having a minor interaction with the drug.

Q: Can Xyliette affect the results of blood tests?

According to the official product information, hormonal contraceptives like Xyliette may interfere with the results of certain laboratory tests. These can include tests for blood clotting factors, fat and protein levels in the blood, and specific binding globulins.

Q: Can Xyliette be used by people with kidney issues?

Official information does not list all kidney conditions as a direct contraindication, but caution is advised for patients whose conditions could be negatively affected by fluid accumulation. Specific serious conditions, such as diabetes with kidney damage (nephropathy), are formally listed as contraindications.

Q: Is there a generic version of Xyliette available?

Xyliette is one brand name for the fixed combination of the synthetic hormones Ethinyl Estradiol and Levonorgestrel. These active ingredients are widely available in the market in generic forms from various manufacturers.

Q: Is Xyliette associated with weight gain or loss?

Weight changes (gain or loss) are observations reported in regulatory documents in association with combination oral contraceptives.

Q: What happens if I stop taking Xyliette suddenly?

Discontinuing the use of Xyliette is associated with the loss of contraceptive protection. Official documents note that the previously increased risk of thromboembolism (blood clots) gradually decreases after use is discontinued.

Q: Do certain antibiotics interact with Xyliette?

Official information indicates that some antibiotics can interact with Xyliette. Specifically, medicines that affect certain liver enzymes can lower the amount of hormone in the bloodstream, which may reduce the drug’s effectiveness. Official information suggests that a back-up method of contraception may be warranted when taking medicines that induce these enzymes.

Q: How long does Xyliette stay in my system after the last use?

Pharmacokinetic data available in regulatory sources describes the elimination half-life for the ethinyl estradiol component as ranging from approximately 7 to 36 hours. This metric represents the time it takes for half of the dose to be cleared from the body.

Q: What should I know about taking Xyliette with alcohol?

Regulatory sources list a minor interaction between the synthetic estrogen component, ethinyl estradiol, and alcohol (ethanol).

Q: Why might Xyliette stop working after a period of time?

A decrease in contraceptive effectiveness is noted as a potential result of interaction with certain other medicines, which can lower the amount of active ingredients in the bloodstream. Effectiveness may also be reduced if tablets are missed or taken incorrectly.

Q: What does the term 'contraindication' mean regarding Xyliette?

A contraindication is a regulatory term describing a condition or factor that serves as a reason to withhold a medical treatment because it would potentially cause harm to the patient. For example, Xyliette is formally contraindicated in women over 35 who smoke.

Q: Is Xyliette metabolized by the liver?

The official warnings regarding severe liver damage (hepatotoxicity) and the contraindication for use in individuals with severe active liver disease indicate the liver is significantly involved in the drug’s processing.

Q: Are there official registry programs for patients using Xyliette?

Official regulatory agencies conduct post-marketing surveillance, which is the monitoring of a drug’s safety after it has been approved. These agencies have established and overseen mandated post-approval studies and registries for certain risks associated with combined oral contraceptives.

Q: Does Xyliette affect blood pressure?

Official documents describe that high blood pressure (hypertension) has been reported in association with drugs in this class. Xyliette is contraindicated in patients with uncontrolled hypertension, and the official label includes statements regarding blood pressure monitoring.

Q: Is Xyliette available in different strengths?

The brand name Xyliette is typically available in one monophasic strength, containing 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol. However, the active ingredients are commercially available in other strengths and dose combinations under different brand and generic names.

How should Xyliette be stored and disposed of?

How to Store and Dispose of Xyliette?

The storage of Xyliette, a combined hormonal contraceptive, must adhere strictly to regulatory conditions to maintain the stability of its active components.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, 68^circmathrmF to 77^circmathrmF (20^circmathrmC to 25^circmathrmC), with permitted excursions up to 86^circmathrmF.
Environment	Keep the medicine away from excess heat and moisture; do not store the product in the bathroom.
Protection	The product must be stored in its original container and kept out of the sight and reach of children to prevent accidental ingestion or misuse.

Disposal Instructions

For disposal, the officially documented method is to use a drug take-back program. If a program is unavailable, mix the tablets with an unappealing substance, seal the mixture in a bag, and discard it in the household trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Austria

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z